Stratification based on AML-BFM protocols was as follows: patients with RUNX1::RUNX1T1, CBFB::MYH11, PML::RARA, normal karyotype with NPM1, or biallelic CEBPA mutations were categorized in the favorable subgroup. This evidence concerns the gene RUNX1 and acute myeloid leukemia.